![Linda Peters](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Linda Peters
Direktor/Vorstandsmitglied bei F3 Platform Biologics, Inc.
Aktive Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Jonathan Peskoff | M | 51 |
F3 Platform Biologics, Inc.
![]() F3 Platform Biologics, Inc. BiotechnologyHealth Technology F3 Platform Biologics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel and practical biotechnology for human use. It handles research, clinical development, and commercialization of new indications surrounding amifostine, a compound that has been previously approved by FDA for indications involving the prevention and treatment of side effects related to cancer treatment and radiation therapy. The company was founded on June 5, 2018 and is headquartered in Atlanta, GA. | 6 Jahre |
James Miller | M | 58 |
F3 Platform Biologics, Inc.
![]() F3 Platform Biologics, Inc. BiotechnologyHealth Technology F3 Platform Biologics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel and practical biotechnology for human use. It handles research, clinical development, and commercialization of new indications surrounding amifostine, a compound that has been previously approved by FDA for indications involving the prevention and treatment of side effects related to cancer treatment and radiation therapy. The company was founded on June 5, 2018 and is headquartered in Atlanta, GA. | 6 Jahre |
Holger Liepmann | M | 72 |
F3 Platform Biologics, Inc.
![]() F3 Platform Biologics, Inc. BiotechnologyHealth Technology F3 Platform Biologics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel and practical biotechnology for human use. It handles research, clinical development, and commercialization of new indications surrounding amifostine, a compound that has been previously approved by FDA for indications involving the prevention and treatment of side effects related to cancer treatment and radiation therapy. The company was founded on June 5, 2018 and is headquartered in Atlanta, GA. | - |
Bernardus MacHielse | M | 63 |
F3 Platform Biologics, Inc.
![]() F3 Platform Biologics, Inc. BiotechnologyHealth Technology F3 Platform Biologics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel and practical biotechnology for human use. It handles research, clinical development, and commercialization of new indications surrounding amifostine, a compound that has been previously approved by FDA for indications involving the prevention and treatment of side effects related to cancer treatment and radiation therapy. The company was founded on June 5, 2018 and is headquartered in Atlanta, GA. | - |
Kevin Rooney | M | 58 |
F3 Platform Biologics, Inc.
![]() F3 Platform Biologics, Inc. BiotechnologyHealth Technology F3 Platform Biologics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel and practical biotechnology for human use. It handles research, clinical development, and commercialization of new indications surrounding amifostine, a compound that has been previously approved by FDA for indications involving the prevention and treatment of side effects related to cancer treatment and radiation therapy. The company was founded on June 5, 2018 and is headquartered in Atlanta, GA. | 2 Jahre |
Daniel Courchesne | M | - |
F3 Platform Biologics, Inc.
![]() F3 Platform Biologics, Inc. BiotechnologyHealth Technology F3 Platform Biologics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel and practical biotechnology for human use. It handles research, clinical development, and commercialization of new indications surrounding amifostine, a compound that has been previously approved by FDA for indications involving the prevention and treatment of side effects related to cancer treatment and radiation therapy. The company was founded on June 5, 2018 and is headquartered in Atlanta, GA. | 5 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
Vereinigte Staaten | 6 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Linda Peters
- Persönliches Netzwerk